Actively Recruiting
Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544
Led by Pfizer · Updated on 2026-05-04
16
Participants Needed
1
Research Sites
10 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the relative bioavailability (rBA) of the Form 2 film-coated tablet of PF-07799933 intended for use in future studies compared to the current Form 1 tablet of PF-07799933 used in Phase 1 studies. Additionally this study will also evaluate the effect of a high-fat meal on the plasma pharmacokinetics (PK), i.e, the rBA compared to overnight fasting, of PF-07799933 and PF-07799544 following concurrent single-dose oral administration of Form 2 film-coated tablet formulation of PF-07799933 with PF-07799544. Finally, this study will also assess the impact of a proton pump inhibitor (a type of acid reducing agent) on PF-07799933 PK of the Form 2 film-coated tablet formulation. These data will be used to inform administration of PF-07799933 and PF-07799544 with food and acid reducing agents in future clinical trials.
CONDITIONS
Official Title
Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female participants of non-childbearing potential and male participants aged 18 to 65 years
- Overtly healthy as determined by medical evaluation including medical history, physical exam, lab tests, vital signs, and ECGs
- Body mass index between 16 and 32 kg/m2
- Total body weight over 50 kg (110 lb)
You will not qualify if you...
- History or evidence of significant uveitis, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (except untreated, asymptomatic seasonal allergies at dosing)
- Any condition affecting drug absorption such as gastrectomy, cholecystectomy, chronic diarrhea, or inflammatory bowel disease
- History of HIV, hepatitis B or C infection
- History or risk factors for retinal vein occlusion or retinal degenerative disease, or blurred vision
- Active bacterial, fungal, or viral infection
- Major surgery within 2 weeks before starting study treatment
- Known or suspected hypersensitivity to study drug or its ingredients
- Any medical or psychiatric condition or lab abnormality increasing study risk or making participation inappropriate
- Use of drugs or supplements within 7 days or 5 half-lives before first study dose; prior use of proton pump inhibitors within 7 days not allowed
- Use of medications that strongly or moderately affect certain liver enzymes or metabolism within specified periods before dosing
- Current use or unwillingness to use required concomitant medications
- Prior investigational drug or vaccine use within 30 days or 5 half-lives before first study dose
- Positive urine drug test (single repeat allowed)
- Use of tobacco or nicotine products within 3 months of screening or positive urine cotinine test
- Screening blood pressure above defined age-specific limits after rest
- Estimated glomerular filtration rate below 60 mL/min/1.73 m2
- Abnormal ECG findings that may affect safety or study interpretation
- Certain abnormal lab test results at screening, confirmed if needed
- History of alcohol abuse, repeated binge drinking, or illicit drug use within 6 months of screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, United States, 06511
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here